$ELDN
Eledon Pharmaceuticals, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021056417 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.848M $3.730M $1.270M
YoY Change -23.65% 164.54% -29.05%
% of Gross Profit
Research & Development $7.658M $615.0K $830.0K
YoY Change 1145.2% -59.24% -63.87%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change -100.0% 0.0%
% of Gross Profit
Operating Expenses $10.51M $6.148M $2.100M
YoY Change 70.88% 110.55% -48.64%
Operating Profit -$10.51M -$6.148M
YoY Change 70.88% 110.55%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $3.000K $4.000K $10.00K
YoY Change -25.0% -85.19% -350.0%
Pretax Income -$10.50M -$6.144M -$2.590M
YoY Change 70.95% 112.6% -36.67%
Income Tax -$686.0K
% Of Pretax Income
Net Earnings -$9.817M -$6.144M -$2.586M
YoY Change 59.78% 112.37% -36.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.66
Diluted Earnings Per Share -$662.6K -$5.532M -$2.755M
COMMON SHARES
Basic Shares Outstanding 14.82M
Diluted Shares Outstanding 14.82M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.04M $114.5M $8.800M
YoY Change -17.87% 960.19% -35.77%
Cash & Equivalents $94.00M $114.5M $8.764M
Short-Term Investments
Other Short-Term Assets $11.00K $17.00K $83.00K
YoY Change -35.29% 13.33% 6.41%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $95.56M $115.1M $9.800M
YoY Change -16.98% 836.08% -35.45%
LONG-TERM ASSETS
Property, Plant & Equipment $222.0K $200.0K $200.0K
YoY Change 11.0% 2757.14% 1900.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $356.0K $449.0K $500.0K
YoY Change -20.71% -34.74% -33.77%
Total Long-Term Assets $81.61M $77.49M $700.0K
YoY Change 5.33% 2551.78% -76.94%
TOTAL ASSETS
Total Short-Term Assets $95.56M $115.1M $9.800M
Total Long-Term Assets $81.61M $77.49M $700.0K
Total Assets $177.2M $192.6M $10.50M
YoY Change -8.0% 1165.51% -42.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.598M $758.0K $200.0K
YoY Change 110.82% 196.09% -73.44%
Accrued Expenses $2.448M $5.400M $900.0K
YoY Change -54.67% 285.71% -25.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.046M $6.100M $1.100M
YoY Change -33.67% 267.25% -43.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $45.00K $164.9M $0.00
YoY Change -99.97% 82350.0% -100.0%
Total Long-Term Liabilities $45.00K $164.9M $0.00
YoY Change -99.97% 82350.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.046M $6.100M $1.100M
Total Long-Term Liabilities $45.00K $164.9M $0.00
Total Liabilities $6.422M $171.1M $1.100M
YoY Change -96.25% 9138.66% -49.63%
SHAREHOLDERS EQUITY
Retained Earnings -$106.1M -$74.49M
YoY Change 42.44% 39.39%
Common Stock $276.8M $96.00M
YoY Change 188.39% 43.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $170.7M $21.51M $9.356M
YoY Change
Total Liabilities & Shareholders Equity $177.2M $192.6M $10.50M
YoY Change -8.0% 1165.51% -42.36%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$9.817M -$6.144M -$2.586M
YoY Change 59.78% 112.37% -36.82%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change -100.0% 0.0%
Cash From Operating Activities -$7.093M -$560.0K -$3.020M
YoY Change 1166.61% -80.56% -38.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $11.04M
YoY Change -100.0%
Cash From Investing Activities $0.00 $11.04M
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000K 95.23M 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -7.093M -560.0K -3.020M
Cash From Investing Activities 0.000 11.04M
Cash From Financing Activities 1.000K 95.23M 0.000
Net Change In Cash -7.092M 105.7M -3.020M
YoY Change -106.71% -3770.49% -165.09%
FREE CASH FLOW
Cash From Operating Activities -$7.093M -$560.0K -$3.020M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
276827000
CY2021Q3 us-gaap Liabilities
Liabilities
6422000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14306788
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14306788
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
14000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-106093000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
170748000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M
us-gaap Restructuring Charges
RestructuringCharges
2292000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2331000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4106000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45000
us-gaap Operating Expenses
OperatingExpenses
12117000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6148000
us-gaap Operating Expenses
OperatingExpenses
27482000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
177170000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6730000
CY2020Q3 us-gaap Restructuring Charges
RestructuringCharges
1802000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
6148000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27482000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12117000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000
eldn Warrant Inducement Expense
WarrantInducementExpense
4829000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10503000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6144000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27475000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16907000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-686000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1775000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9817000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6144000
us-gaap Net Income Loss
NetIncomeLoss
-25700000
us-gaap Net Income Loss
NetIncomeLoss
-16907000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.81
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14815852
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1114133
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14820822
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1006008
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
190596000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
21506000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
us-gaap Net Income Loss
NetIncomeLoss
-25700000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2043000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9817000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
170748000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
9465000
eldn Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5191000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1194000
eldn Adjustments To Additional Paid In Capital Fair Value Of Options Assumed In Acquisitions
AdjustmentsToAdditionalPaidInCapitalFairValueOfOptionsAssumedInAcquisitions
3278000
eldn Adjustments To Additional Paid In Capital Fair Value Of Warrants Assumed In Acquisitions
AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsAssumedInAcquisitions
12944000
eldn Warrants Issued During Period Inducement Expense
WarrantsIssuedDuringPeriodInducementExpense
4829000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1512000
us-gaap Net Income Loss
NetIncomeLoss
-16907000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
9356000
CY2020Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1194000
CY2020Q3 eldn Adjustments To Additional Paid In Capital Fair Value Of Options Assumed In Acquisitions
AdjustmentsToAdditionalPaidInCapitalFairValueOfOptionsAssumedInAcquisitions
3278000
CY2020Q3 eldn Adjustments To Additional Paid In Capital Fair Value Of Warrants Assumed In Acquisitions
AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantsAssumedInAcquisitions
12944000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
878000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6144000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
21506000
us-gaap Net Income Loss
NetIncomeLoss
-25700000
us-gaap Net Income Loss
NetIncomeLoss
-16907000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
5000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
134000
eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
133000
eldn Warrant Inducement Expense
WarrantInducementExpense
4829000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5851000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1512000
eldn Deferred Tax Liability
DeferredTaxLiability
1775000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
55000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-771000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1980000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4011000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-140000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-133000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19705000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5779000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
11035000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11035000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
95226000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5191000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
450000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-449000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
100417000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20154000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
105673000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114195000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8791000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94041000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114464000
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1000
eldn Increase In Operating Lease Asset And Liability Due To Lease Modification
IncreaseInOperatingLeaseAssetAndLiabilityDueToLeaseModification
219000
eldn Issuance Of Common Stocks In Acquisition
IssuanceOfCommonStocksInAcquisition
1194000
eldn Issuance Of Non Voting Convertible Preferred Stock In Acquisition
IssuanceOfNonVotingConvertiblePreferredStockInAcquisition
69723000
eldn Fair Value Of Options Assumed In Acquisition
FairValueOfOptionsAssumedInAcquisition
3278000
eldn Fair Value Of Warrant Assumed In Acquisition
FairValueOfWarrantAssumedInAcquisition
12944000
us-gaap Net Income Loss
NetIncomeLoss
-25700000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9800000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94000000.0
CY2021Q3 eldn Working Capital
WorkingCapital
91500000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-106100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.58%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based transactions, accruals for liabilities, fair value of assets acquired and liabilities assumed in a business combination, impairment of long lived assets, including goodwill, and other matters that affect the condensed consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the <span style="color:#000000;">condensed </span>consolidated financial statements. </p>
eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9200000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9200000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9817000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6144000
us-gaap Net Income Loss
NetIncomeLoss
-25700000
us-gaap Net Income Loss
NetIncomeLoss
-16907000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.81
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14815852
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1114133
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14820822
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1006008
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
674295
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1828531
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.29%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications of prior period amounts have been made to conform to the current period presentation.</p>
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
67000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
359000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1157000
CY2021Q3 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
1097000
CY2020Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
89000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
50000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
41000
CY2020Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
110000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
11000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
38000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1517000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1435000
CY2021Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
783000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
31000
CY2021Q3 eldn Accrued Severance Current
AccruedSeveranceCurrent
337000
CY2020Q4 eldn Accrued Severance Current
AccruedSeveranceCurrent
12000
CY2021Q3 eldn Accrued Clinical Current
AccruedClinicalCurrent
912000
CY2020Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
258000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
52000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9000
CY2021Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
148000
CY2020Q4 eldn Accrued Financing Costs
AccruedFinancingCosts
450000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
146000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2271000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
973000
CY2021Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
63000
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
50000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
189000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
143000
CY2021Q3 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
us-gaap Operating Lease Cost
OperatingLeaseCost
145000
us-gaap Operating Lease Payments
OperatingLeasePayments
146000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0318
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
45000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
181000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
226000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
222000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
177000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
45000
CY2021Q3 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2021Q3 eldn Contingent Liability
ContingentLiability
0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2043000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
878000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5851000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1512000
CY2020Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
120000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
120000
CY2020Q3 eldn Business Acquisition Pro Forma Net Income Loss And Other Comprehensive Income Loss
BusinessAcquisitionProFormaNetIncomeLossAndOtherComprehensiveIncomeLoss
-5375000
eldn Business Acquisition Pro Forma Net Income Loss And Other Comprehensive Income Loss
BusinessAcquisitionProFormaNetIncomeLossAndOtherComprehensiveIncomeLoss
-19140000
CY2020Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2700000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2700000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0

Files In Submission

Name View Source Status
0001564590-21-056417-index-headers.html Edgar Link pending
0001564590-21-056417-index.html Edgar Link pending
0001564590-21-056417.txt Edgar Link pending
0001564590-21-056417-xbrl.zip Edgar Link pending
eldn-10q_20210930.htm Edgar Link pending
eldn-10q_20210930_htm.xml Edgar Link completed
eldn-20210930.xsd Edgar Link pending
eldn-20210930_cal.xml Edgar Link unprocessable
eldn-20210930_def.xml Edgar Link unprocessable
eldn-20210930_lab.xml Edgar Link unprocessable
eldn-20210930_pre.xml Edgar Link unprocessable
eldn-ex311_9.htm Edgar Link pending
eldn-ex312_7.htm Edgar Link pending
eldn-ex321_6.htm Edgar Link pending
eldn-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending